10-Q: MDB Capital Holdings Reports First Quarter 2024 Results with Increased Operating Losses

MDB Capital Holdings reported a net loss of $7.6 million for the first quarter of 2024, driven by unrealized losses on investment securities and increased operating costs.

Summary

• MDB Capital Holdings reported a net loss of $7.6 million for the first quarter of 2024, compared to a net loss of $1.97 million in the same period of 2023.
• The increased loss was primarily due to a $747,268 unrealized loss on investment securities held by their licensed broker-dealer, compared to a gain of $54,779 in the prior year.
• Operating costs increased significantly to $7.3 million, up from $2.3 million in Q1 2023, driven by higher compensation, professional fees, and research and development expenses.
• General and administrative costs rose to $7 million, a substantial increase from $2.2 million in the prior year, with compensation expenses being a major contributor.
• Research and development costs, net of grants, increased to $277,582 from $31,592 in the same period last year, due to a decrease in grant funding.
• The company's cash and cash equivalents decreased to $5.5 million from $6.1 million at the end of 2023.
• The company's total assets decreased to $40.9 million from $43 million at the end of 2023.
• The company's total liabilities increased to $7.4 million from $5.7 million at the end of 2023.

Sentiment

Score: 3

Explanation: The document indicates a significant increase in net losses and operating costs, coupled with a decrease in cash and a material weakness in internal controls. This suggests a negative outlook from an investment perspective.

Positives

• Interest income increased to $337,852, up from $187,291 in the same period last year, due to interest generated on U.S. Treasury Bills.
• The company's working capital increased to $27.3 million, up from $19.8 million in the same period last year, primarily due to funds received from the initial public offering in 2023.

Negatives

• The company's net loss significantly increased to $7.6 million in Q1 2024, compared to $1.97 million in Q1 2023.
• Unrealized losses on investment securities were a major factor in the increased loss.
• Operating costs more than tripled compared to the same period last year.
• General and administrative costs saw a substantial increase, driven by higher compensation and professional fees.
• Research and development costs increased significantly due to a decrease in grant funding.
• Cash and cash equivalents decreased by approximately $600,000 during the quarter.

Risks

• The company's financial performance is heavily influenced by the performance of its investment securities, which can be volatile.
• The company's operating costs are increasing significantly, which could impact profitability.
• The company is reliant on grant funding for its research and development activities, which can fluctuate.
• The company's internal controls over financial reporting were deemed not effective at the reasonable assurance level.
• The company is subject to the uniform net capital rule, which may limit its ability to issue dividends.

Future Outlook

The company intends to use the funds from its IPO for the development of Invizyne, identifying and developing new partner companies, and general corporate and working capital requirements. The company is also continuing to monitor the economic environment and will adjust its business and financing plans as more information becomes available.

Management Comments

• The company's management believes that disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level.
• Management does not expect that the disclosure controls and procedures or the internal control over financial reporting will prevent or detect all errors and all fraud.

Industry Context

The company operates in the financial services and biotechnology sectors, which are both subject to significant market and regulatory risks. The company's performance is influenced by the overall health of the capital markets and the success of its technology development efforts. The increased operating costs and net losses are not uncommon for companies in the early stages of growth, particularly those involved in research and development.

Comparison to Industry Standards

• The company's significant increase in operating costs and net losses is worse than many established companies in the financial services and biotechnology sectors.
• The company's reliance on investment securities for revenue generation is a higher risk strategy than many of its peers.
• The company's internal control weaknesses are a concern and need to be addressed to meet industry standards.
• The company's cash burn rate is high, which is not uncommon for early-stage companies, but needs to be monitored closely.
• The company's performance is not directly comparable to large, established financial institutions or biotechnology companies, but it is important to benchmark against similar early-stage companies.

Related Party Transactions

• The principal members of the Company have a controlling interest in MDB Capital, S.A., a company organized and based in Nicaragua that provides outsourced services to the Company and other non-related entities.
• During the three months ended March 31, 2024 and 2023, the Company paid $320,792 and $301,702, respectively, for contracted labor from MDB Capital, S.A.
• PatentVest engaged in transactions with ENDRA Life Sciences Inc, a company for which two of our executive officers serve as board members.

Stakeholder Impact

• Shareholders will be negatively impacted by the increased net loss and decreased equity.
• Employees may be impacted by potential cost-cutting measures if the company's financial performance does not improve.
• Customers of the broker-dealer may be impacted by the company's compliance with net capital requirements.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company is implementing measures to remediate the material weakness in internal control over financial reporting.
• The company will continue to monitor the economic environment and adjust its business and financing plans as needed.
• The company will continue to use the funds from its IPO for the development of Invizyne, identifying and developing new partner companies, and general corporate and working capital requirements.

Key Dates

Keywords

MDB Capital Holdings, financial results, quarterly report, net loss, investment securities, operating costs, research and development, broker-dealer, intellectual property, technology development, internal controls, public offering